BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17118955)

  • 1. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction.
    Goetze JP; Mogelvang R; Maage L; Scharling H; Schnohr P; Sogaard P; Rehfeld JF; Jensen JS
    Eur Heart J; 2006 Dec; 27(24):3004-10. PubMed ID: 17118955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide.
    Mogelvang R; Goetze JP; Schnohr P; Lange P; Sogaard P; Rehfeld JF; Jensen JS
    J Am Coll Cardiol; 2007 Oct; 50(17):1694-701. PubMed ID: 17950153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.
    Romano S; Necozione S; Guarracini L; Fratini S; Cisternino P; di Orio F; Penco M
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):238-44. PubMed ID: 19262210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study.
    Morillas P; Castillo J; Quiles J; Nuñez D; Guillén S; Maceira A; Rivera M; Bertomeu V
    Rev Esp Cardiol; 2008 Sep; 61(9):972-5. PubMed ID: 18775240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study.
    Nakamura M; Tanaka F; Sato K; Segawa T; Nagano M
    J Card Fail; 2005 Dec; 11(9):705-12. PubMed ID: 16360967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
    Goode KM; Clark AL; Cleland JG
    Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients.
    Choi SY; Lee JE; Jang EH; Kim MO; Baek H; Ki CS; Park SW; Kim DJ; Huh WS; Oh HY; Kim YG
    Nephron Clin Pract; 2008; 110(2):c93-100. PubMed ID: 18815449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
    Vasan RS; Benjamin EJ; Larson MG; Leip EP; Wang TJ; Wilson PW; Levy D
    JAMA; 2002 Sep; 288(10):1252-9. PubMed ID: 12215132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide.
    Freitag MH; Vasan RS
    Heart Fail Monit; 2003; 4(2):38-44. PubMed ID: 14724717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study.
    Krittayaphong R; Boonyasirinant T; Saiviroonporn P; Udompunturak S
    Coron Artery Dis; 2008 Nov; 19(7):481-7. PubMed ID: 18923244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.